Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > My order just got filled
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(33)
•••
Comment by Inthepezon Sep 21, 2022 2:06pm
96 Views
Post# 34977025

RE:My order just got filled

RE:My order just got filled

No one cares dumpster. That's why youre on their ignore list along with your other handles. But what it interesting is you requesting your comment to be deleted as Czechcashings. Don't worry dumpster I kept that the receipts and sending it to appropriate moderaters. keep talking to yourself as stockings lover LOL! 



Duster340 wrote: had it in all morning 3k @62.  it replaces what i sold on friday @70.  in the last 4 months i made $1,226 clear profit on my micro trades of only 3k each time, would have gone biger but liquidity in the stock limits what you can trade. 11 trades total were made all just for fun, why not make a little cash while i wait.  also grew my core holdings. now expecting news next week and a possible bump in share price.
glta 

 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities